# 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis

> **NCT06903884** · PHASE3 · RECRUITING · sponsor: **The University of Hong Kong** · enrollment: 94 (estimated)

## Conditions studied

- Vernal Keratoconjunctivitis

## Interventions

- **DRUG:** 3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion
- **DRUG:** 0.1% Cyclosporin A cationic ophthalmic emulsion

## Key facts

- **NCT ID:** NCT06903884
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-09
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06903884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06903884, "3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06903884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*